Overview

A Phase I Trial of Satraplatin Plus Radiation Therapy for Prostate Cancer Patients With Biochemical Recurrence

Status:
Terminated
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
This study is designed to measure the impact of Satraplatin plus radiation therapy to the bed of the prostate in patients who have developed biochemical failure of their prostate cancer. The main objective of this study is to determine the maximum tolerated dose and dose limiting toxicity for the combination of satraplatin and radiation therapy and to determine the recommended dose for subsequent Phase II trials.
Phase:
Phase 1
Details
Lead Sponsor:
Agennix
Treatments:
Satraplatin